Gamida Cell Ltd.

GMDA

IL0011552663

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:54:51 2024-05-24 EDT			5-day change	1st Jan Change
0.017 ^USD	+2.41%		0.00%	-95.88%

05-23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI

Gamida Cell Ltd. Announces Resignation of Director

May 21, 2021 at 04:16 pm

On May 20, 2021, Michael S. Perry provided notice to Gamida Cell Ltd. of his intention to resign from the Company’s Board of Directors effective immediately.

Latest news about Gamida Cell Ltd.

Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	04-09	CI
Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	04-04	CI
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	03-28	MT
Top Premarket Decliners	03-28	MT
Top Midday Decliners	03-27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27	MT
Transcript : Gamida Cell Ltd., Q4 2023 Earnings Call, Mar 27, 2024	03-27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	03-27	MT
Top Premarket Decliners	03-27	MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Gamida Cell Ltd. Announces Cessation of Executives	03-27	CI
Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC	03-26	CI
JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	01-29	MT
Gamida Cell Exploring Strategic Alternatives; Shares Rise	01-29	MT
Gamida Cell Actively Pursuing Strategic Alternatives	01-28	CI
Transcript : Gamida Cell Ltd. - Special Call	12-04
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	11-15	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	11-15	MT
Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director	11-15	CI
Transcript : Gamida Cell Ltd., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting	11-04	CI
Transcript : Gamida Cell Ltd. - Shareholder/Analyst Call	23-10-19
Gamida Cell Reports New Early Data in Phase 1 Study of Cancer Treatment Candidate	23-10-16	MT

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GAMIDA CELL LTD.	-95.88%	2.62M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-0.90%	22.1B
GENMAB A/S	-9.56%	18.34B
WUXI APPTEC CO., LTD.	-41.70%	16.59B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B